Phase 3 study of mipomersen for the treatment of heterozygous familial hypercholesterolemia (heFH) - MPR
Links shared publicly online about this topic.
- 1,392total visits
Phase 3 study of mipomersen for the treatment of heterozygous familial hypercholesterolemia (heFH) - MPR
empr.com —
View full resource at empr.com
Tags: Pharma, Phase 3 Clinical Trial, Genzyme, News
Most Recently Shared on February 10, 2010 at 4:43 pm By:
MPR News: Phase 3 study of mipomersen for the treatment of heterozygous familial hypercholesterolemia (heFH): Genz... http://bit.ly/cRpcgd
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
medicalnewstoday.com — “Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its” View full resource at medicalnewstoday.com
Most Recently Shared on February 12, 2010 at 1:16 pm By:
MNT Cholesterol News Health News
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint http://mnt.to/3xxC #cholesterol
Mipomersen Phase 3 Study In Patients With Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint
mnt.to — “Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its” View full resource at mnt.to
Most Recently Shared on February 12, 2010 at 11:38 am By:
MedicalNewsToday: Mipomersen Phase 3 Study In Patients With Heterozygous Familial: http://bit.ly/bka8e4 Full http://bit.ly/dn0m0P
Advertisement
